ABSTRACT -The authors report the history of spinocerebellar ataxia 10 (SCA10), since its first report in a large Portuguese-ancestry Family with autosomal dominant pure cerebellar ataxia, till the final identification of further families without Mexican ancestry. These families present a quite different phenotype from those SCA10 families described in Mexico.
1
. They are characterized by a large genotypic and phenotypic heterogeneity. About 30 types of SCA have been described to date and a genic locus is already known in 11 out of this increasing group of diseases. Machado-Joseph´s disease or SCA type 3 is the most prevalent form of SCA in several series around the world and in Brazil [1] [2] [3] [4] . SCA type 10 is an autosomal dominant form of SCA caused by a repeating expansion of the pentanucleotide ATTCT of an intronic region of SCA10 gene. SCA type 10 was originally identifi ed only in Mexican familes and had a phenotype characterized by a combination of cerebellar ataxia and epilepsy [5] [6] [7] [8] [9] . In 2004, Teive et al. described 28 patients out of 5 Brazilian families who presented a homogeneous phenotype of pure cerebellar ataxia, but without epilepsy. Those families were identifi ed as having the same repeating expansion of the pentanucleotide AT-TCT, described in SCA type 10. 10 Nowadays, SCA type 10 is the second most common form of SCA in Mexico and Brazil, after SCA type 3 11 . In this paper, the authors describe the historic trajetory of the fi rst Brazilian family with SCA type 10, since its fi rst clinical description till the fi nal molecular genetic diagnosis. SCA in Brazil -Since 1996 many Neurogenetics Services identifi ed different forms of SCA in Brazil, based on clinical and molecular genetics studies. SCA type 3, or Machado-Joseph disease, turned out to be the most common form of SCA, regardless the geographical background, followed by much less frequent forms of SCA such as types 1, 2 and 7 [2] [3] [4] . SCA type 10 was fi rst described by Grewal et al, in 1998, when they evaluated 11 patients of a Mexican family affected by an AD form of cerebellar ataxia complicated by concomitant epilepsy 6 . In 1999, the locus of this new form of SCA was mapped independently by Zu et al. 7 and Matsuura et al. 8 , including the three families used in the study to identify the mutation 13 . The clinical fi ndings included, in addition to cerebellar ataxia and epilepsy (present in 72.2% of the affected members), peripheral polyneuropathy (66%), mild pyramidal signs and cognitive dysfunction in a few patients. Epilepsy, as a key feature of the SCA 10 phenotype, was confi rmed by a further study of Grewal at el in 2002 9 . Therefore, SCA type 10 described in Mexican families showed homogenous phenotype characterized by: 1) Mexican ancestry; 2) pure cerebellar ataxia, frequently complicated by epilepsy; and 3) antecipation phenomena of the age of onset in consecutive generations In 1992, a collaborative work with the Genetic Unit (Prof. Anita Harding), at the Institute of Neurology, Queen Square, London, was started and the fi rst family 15 with SCA type 10 was genetically evaluated for types 3, and later 1 and 2, which loci were already known by that time, and the results were negative. Figure shows the letter of Prof. Anita Harding reporting the negative results of those molecular genetic studies. Subsequently, from 1993 to 1997, molecular genetic studies of several families with AD cerebellar ataxias were conducted in Montreal, Canada, by Prof. Guy Rouleaux. At that time, Dr. Isabel Silveira, from the UnIGENe, IBMC, University of Porto, Porto, Portugal, and Dr. Iscia Lopes-Cendes, from State University of Campinas (UNICAMP), São Paulo, Brazil, were working at Prof. Rouleuax Service and were the key persons with whom our group kept contact. Among the large number of samples coming from several families affected by different forms of AD SCA, other families with pure cerebellar AD late onset SCA were later identifi ed as having SCA type 10. At that time, other forms of SCA (eg, types 1, 2 and 3, and DRPLA) were screened and the results were negative.
The Study Group for the Hereditary Ataxias -
From 1998 on, the molecular genetic studies were performed at the Medical Genetics Service of UNI-CAMP, Campinas, Brazil, under the supervision of Prof. Iscia Lopes-Cendes. At that time, the panel of SCA included SCA types 1,2,3,6,7, and DentatorubralPallidoluysian Atrophy (DRPLA).
The tests for detection of SCA type 6 mutation created great expectation. Nevertheless the results were negative in several families with "pure" cerebellar ataxia.
In 1999, Professor Salmo Raskin from the Genetika Laboratory, started genetic studies of SCA patients, followed with the foundation of the Laboratory of Molecular Biology at the Hospital de Clínicas, Federal University of Paraná by Prof. Lineu C. Werneck. At tis time, genetic testing for SCA types 1,2,3,6,7,8,12 and 14, and DRPLA became available, although the particular group of SCA with "pure" cerebellar ataxia still was a genetic puzzle.
In 2004, Raskin introduced in his Laboratory a so called panel of cerebellar ataxias, including all known SCA genes, in particular a recently new described form of SCA in Mexican patients, SCA type 10. He re-studied a patient coming from a family with late-onset "pure" cerebellar ataxia without epilepsy and surprisingly it turned out that this patient and family had the SCA type 10 mutation. With this unexpected fi nding, other four families with late onset "pure" SCA were investigated for SCA type 10 with positive results. Subsequently, three other families were diagnosed as SCA type 10, all of them with "pure" cerebellar ataxia without epilepsy.
In 2005, the fi rst case of SCA type 10 with epilepsy was diagnosed in a female patient with early onset SCA associated with cognitive dysfunction and with a negative family history. This case of SCA type 10 showed that a reduced gene penetrance may occur in SCA type 10, with a clinical expression of early onset SCA associated with dementia, when the repeat expansion size is relatively small compared to other patients with SCA type 10 16 .
In conclusion, after 20 years of clinical investigation and with the introduction of molecular genetics techniques allowing the identifi cation of an ever increasing number of SCA causing genes, we could defi ne that SCA type 10 is the second most common form of SCA in México and Brazil. Furthermore, we could clearly identify two distinct phenotypic presentation of SCA type 10, one Mexican (with epilepsy) and other Brazilian (without epilepsy) 10, 16 .
